Furthermore, after observing that EGCG could inhibit ERCC1/XPF and, along with Pro-EGCG, could sensitize lung cancer cells to cisplatin in vitro, we assessed the effects of combination treatment with cisplatin and Pro-EGCG in vivo. Here, ERCC4 is linked to lung carcinoma.